Background Prostate-specific membrane antigen (PSMA) positron emission tomography
(PET)/computed tomography (CT) has become an increasingly established imaging …

Prostate-specific membrane antigen PET/CT for primary staging of prostate cancer is
becoming increasingly popular due to simultaneous assessment of whole-body disease …

Prostate cancer is the second most common cause of malignancy among men, with bone
metastasis being a significant source of morbidity and mortality in advanced cases …

Purpose Uncertain focal bone uptake (UBU) with intensive radiopharmaceutical avidity are
frequently observed in patients undergoing [18F] PSMA-1007 PET/CT for the detection of …

Aim Despite increasing use for the detection of biochemically recurrent prostate cancer
(rPC), the diagnostic accuracy of positron emission tomography/computed tomography …

Radiolabelled prostate-specific membrane antigen (PSMA)-based PET–CT has been shown
in numerous studies to be superior to conventional imaging in the detection of nodal or …

Simple Summary This study investigates a promising avenue for improving the diagnosis
and treatment of triple-negative breast cancer (TNBC), a highly aggressive form of breast …

Simple Summary In this paper we systematically evaluate the evidence regarding the role of
[68Ga] PSMA PET/CT for clinical suspicions of prostate cancer in patients with or without …

The aim of this prospective clinical study was to evaluate the potential of the prostate specific
membrane antigen (PSMA) targeting ligand,[68Ga]-PSMA–Glu–NH–CO–NH–Lys-2 …

Background A number of radiopharmaceuticals are available for the detection of recurrent
prostate cancer (rPC), but few comparative imaging trials have been performed comparing …